Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), announced today that shareholders approved all management proposals with a large majority at the ordinary virtual Annual General Meeting held on June 23, 2026. The approvals ranged between 98.67% and 98.72% for each agenda item, reflecting strong shareholder support for the company's strategic direction.
Key resolutions included the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Additionally, shareholders elected Mr. Jack Yefei Ling as a new member of the Supervisory Board and approved an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members. The high attendance, including postal votes, represented 80.55% of the current capital stock.
The election of Mr. Ling brings fresh perspective to the board as Heidelberg Pharma continues to advance its ATAC technology platform, which uses Amanitin, a compound derived from the green death cap mushroom, to develop cancer therapies. The company's lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA in multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the FDA. A second candidate, HDP-102, is in clinical development for Non-Hodgkin Lymphoma, while HDP-103 and HDP-104 are available for partnering after completing preclinical development.
The approval of the remuneration report signals shareholder confidence in the alignment of executive compensation with company performance. The reduction in the size of the Supervisory Board aims to streamline governance and enhance decision-making efficiency.
For more details on the voting results and other AGM information, visit https://heidelberg-pharma.com/en/agm. Heidelberg Pharma is listed on the Frankfurt Stock Exchange under ISIN DE000A11QVV0 and symbol HPHA. More information about the company and its ATAC technology is available at www.heidelberg-pharma.com.
